Vascular smooth muscle contractility assays for inflammatory and immunological mediators

International Immunopharmacology

Volumn 10, Issue 11, 2010, Pages 1344-1353

  Marceau, François ^a   deBlois, Denis ^b   Petitclerc, Eric ^c   Levesque, Luc ^d   Drapeau, Guy ^a   Audet, Ritchie ^e   Godin, Denis ^f   Larrivée, Jean François ^a   Houle, Steeve ^a   Sabourin, Thierry ^a   Fortin, Jean Philippe ^a   Morissette, Guillaume ^a   Gera, Lajos ^g   Bawolak, Marie Thérèse ^a   Koumbadinga, Gérémy Abdull ^a   Bouthillier, Johanne ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Héma Québec ^*  (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITÉ LAVAL   (Canada)

^f Université Laval   (Canada)

^g UNIVERSITY OF COLORADO   (United States)

Author keywords

Anaphylatoxin C5a; Bradykinin; Histamine; Interleukin 1; Rabbit aorta; Vascular smooth muscle contractility

Indexed keywords

[[4 [2 [[BIS(CYCLOHEXYLAMINO)METHYLENE]AMINO] 3 (2 NAPHTHYL)PROPIONAMIDO]PHENYL]METHYL]TRIBUTYLPHOSPHONIUM CHLORIDE; ANAPHYLATOXIN; ANATIBANT; B 10380; B 9430; B 9972; BRADYKININ; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR AGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; ICATIBANT; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; PROTEINASE; RECOMBINANT HEMOGLOBIN; UNCLASSIFIED DRUG;

BIOASSAY; CELL INTERACTION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG STRUCTURE; GENE TECHNOLOGY; HUMAN; INFLAMMATION; KNOCKOUT GENE; MEDIATOR; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE CONTRACTILITY; UMBILICAL VEIN; VASCULAR SMOOTH MUSCLE;

ANIMALS; BIOLOGICAL ASSAY; BLOOD VESSELS; CELL COMMUNICATION; CYTOKINES; GENE EXPRESSION; HUMANS; INFLAMMATION MEDIATORS; MALE; MICE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE SYNTHASE TYPE II; ORGAN CULTURE TECHNIQUES; PEPTIDE HYDROLASES; RATS; RECEPTOR, BRADYKININ B2; UMBILICAL VEINS;

EID: 77958153285     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.08.016     Document Type: Review

References (71)

1. Vane J.R. Adventures and excursions in bioassay - the stepping stones to prostacyclin. Postgrad Med J 1983, 59:743-758.
2. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373-376.
3. 9-BK in plasma. Can J Physiol Pharmacol 1981, 59:131-138.
4. Arunlakshana O., Schild H.O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 1959, 14:48-58.
5. Kalsner S., Nickerson M. A method for the study of mechanisms of drug disposition in smooth muscle. Can J Physiol Pharmacol 1968, 46:719-730.
6. Mulvany M.J., Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1997, 41:19-26.
7. Tschöpe C., Walther T., Escher F., Spillmann F., Du J., Altmann C., et al. Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. FASEB J 2005, 19:2057-2059.
8. Kristek F., Török J., Šikulová J. Morphological and functional alterations in endothelium, smooth muscle, and nerve fibers in rabbit aorta after storage at 4°C. Cryobiology 1993, 30:376-385.
9. Sato K., Ozaki H., Karaki H. Changes in cytosolic calcium leve; in vascular smooth muscle strip measured simultaneously with contraction using fluorescent calcium indicator Fura2. J Pharmacol Exp Ther 1988, 246:294-300.
10. Ellershaw D.C., Gurney A.M. Mechanisms of hydralazine induced vasodilation in rabbit aorta and pulmonary artery. Br J Pharmacol 2001, 134:621-631.
11. Swafford A.N., Harrison-Bernard L.M., Dick G.M. Knockout mice reveal that the angiotensin II type 1B receptor links to smooth muscle contraction. Am J Hypertens 2007, 20:335-337.
12. Corbacho A.M., Eiserich J.P., Zuniga L.A., Valacchi G., Villablanca A.C. Compromised aortic vasoreactivity in male estrogen receptor-α-deficient mice during acute lipopolysaccharide-induced inflammation. Endocrinology 2007, 148:1403-1411.
13. Gunnett C.A., Lund D.D., MvDowell A.K., Faraci F.M., Heistad D.D. Mechanisms of inducible nitric oxide synthase-mediated vascular dysfunction. Arterioscler Throm Vasc Biol 2005, 25:1617-1622.
14. Altura B.M., Malaviya D., Reich C.F., Orkin L.R. Effects of vasoactive agents on isolated human umbilical arteries and veins. Am J Physiol 1972, 222:345-355.
15. Marceau F., deBlois D., Laplante C., Petitclerc E., Pelletier G., Grose J.H., et al. Contractile effect of the chemotactic factors f-Met-Leu-Phe and C5a on the human isolated umbilical artery. Role of cyclooxygenase products and tissue macrophages. Circ Res 1990, 67:1059-1070.
16. 2 receptors on the venoconstrictor action of bradykinin. J Pharmacol Exp Ther 1994, 269:1136-1143.
17. Gobeil F., Pheng L.H., Badini I., Nguyen-Le X.K., Pizard A., Rizzi A., et al. Receptors for kinins in the human isolated umbilical vein. Br J Pharmacol 1996, 118:289-294.
18. 2 receptor antagonist. An in vitro study. Hypertension 1997, 29:951-956.
19. 2 receptor: inter-species variability and dissociation between binding and functional responses. Br J Pharmacol 1999, 126:1083-1090.
20. Meini S., Lecci A., Carini F., Tramontana M., Giuliani S., Maggi C.A., et al. In vitro and in vivo activity of analogues of the kinin B2 receptor antagonist MEN1 1270. Can J Physiol Pharmacol 2002, 80:293-302.
21. 2 receptor. Int Immunopharmacol 2003, 3:1529-1536.
22. Bawolak M.T., Marceau F. Does zaltoprofen antagonize the bradykinin receptors?. Regul Peptides 2007, 140:125-130.
23. 2 receptors. Br J Pharmacol 2009, 158:1375-1386.
24. 8]-bradykinin): pharmacologic profile and effective induction of receptor degradation. J Pharmacol Exp Ther 2007, 323:534-546.
25. 2 receptor. Hypertension 2000, 35:1319-1325.
26. 2 receptor. Peptides 2001, 22:1397-1402.
27. 2 receptor antagonist B-9430: pharmacological characterization and use in live cell imaging. Peptides 2008, 29:1626-1630.
28. Gras J. Icatibant for hereditary angioedema. Drugs Today (Barc) 2009, 45:855-864.
29. Bas M., Greve J., Stelter K., Bier H., Stark T., Hoffmann T.K., Kojda G. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med 2010, 56:278-283.
30. Schmidt PW, Hirschl MM, Trautinger F. Treatment of angiotensin-converting enzyme inhibitor-related angioedema with the bradykinin B2 receptor antagonist icatibant. J Am Acad Dermatol 2010; in press (). doi:10.1016/j.jaad.2010.03.023.
31. Weller K, Magerl M, Maurer M. Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant. J Eur Acad Dermatol Venereol 2010; in press (). doi:10.1111/j.1468-3083.2010.03712.x.
32. Regoli D., Barabé J., Park W.K. Receptors for bradykinin in rabbit aortae. Can J Physiol Pharmacol 1977, 55:855-867.
33. 9-bradykinin in vitro and in vivo. Br J Pharmacol 1987, 92:257-264.
34. 9-bradykinin in vivo and in vitro. Immunopharmacology 1989, 17:187-198.
35. 1 receptors in isolated rabbit aorta by using metabolic inhibitors. Eur J Pharmacol 1994, 271:551-555.
36. 1 receptors for kinins. Pharmacol Rev 1998, 50:357-386.
37. 1 receptor in fresh or cultured rabbit aortic smooth muscle: role of NF-κB. Am J Physiol Heart Circ Physiol 2002, 283:H227-H237.
38. 1 receptors induced by tissue injury. J Immunol 1998, 160:1419-1426.
39. 1 receptor expression in rabbit aortic smooth muscle. Eur J Pharmacol 2009, 606:233-239.
40. Marceau F., Petitclerc E., deBlois D., Pradelles P., Poubelle P.E. Human interleukin-1 induces a rapid relaxation of the rabbit isolated mesenteric artery. Br J Pharmacol 1991, 103:1367-1372.
41. Petitclerc E., Poubelle P.E., Marceau F. Rapid protein synthesis and turnover is involved in interleukin-1-induced relaxation of the rabbit isolated mesenteric artery. Analysis of the arachidonate cascade. J Pharmacol Exp Ther 1994, 268:1419-1425.
42. Beasley D., Cohen R.A., Levinsky N.G. Interleukin 1 inhibits contraction of vascular smooth muscle. J Clin Invest 1989, 83:331-335.
43. Beasley D. Interleukin 1 and endotoxin activate soluble guanylate cyclase in vascular smooth muscle. Am J Physiol 1990, 259:R38-R44.
44. Petitclerc E., Abel S., deBlois D., Poubelle P.E., Marceau F. Effect of interleukin 1 receptor antagonist on three types of responses to interleukin 1 in rabbit isolated blood vessels. J Cardiovasc Pharmacol 1992, 19:821-829.
45. Rioux F., Petitclerc E., Audet R., Drapeau G., Fielding R.M., Marceau F. Recombinant human hemoglobin inhibits both constitutive and cytokine-induced nitric oxide-mediated relaxation of rabbit isolated aortic rings. J Cardiovasc Pharmacol 1994, 24:229-237.
46. Gan B.S., Hollenberg M.D., MacCannell K.L., Lederis K., Winkler M.E., Derynck R. Distinct vascular actions of epidermal growth factor-urogastrone and transforming growth factor-α. J Pharmacol Exp Ther 1987, 242:331-337.
47. Petitclerc E., Poubelle P.E., Marceau F. Epidermal growth factor-induced rapid relaxation of the isolated rabbit mesenteric artery. Eur J Pharmacol 1994, 259:91-94.
48. Vu T.K., Hung D.T., Wheaton V.I., Coughlin S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991, 22:1057-1068.
49. Vergnolle N. Protease-activated receptors as drug targets in inflammation and pain. Pharmacol Ther 2009, 123:292-309.
50. Yang S.G., Laniyonu A., Saifeddine M., Moore G.J., Hollenberg M.D. Actions of thrombin and thrombin receptor peptide analogues in gastric and aortic smooth muscle: development of bioassays for structure-activity studies. Life Sci 1992, 51:1325-1332.
51. Antonaccio M.J., Normandin D., Serafino R., Moreland S. Effects of thrombin and thrombin receptor activating peptides on rat aortic vascular smooth muscle. J Pharmacol Exp Ther 1993, 266:125-132.
52. Ku D.D., Zaleski J.K. Receptor mechanism of thrombin induced endothelium-dependent and endothelium-independent coronary vascular effects in dogs. J Cardiovasc Pharmacol 1993, 22:609-616.
53. Godin D., Marceau F., Beaulé C., Rioux F., Drapeau G. Aminopeptidase modulation of pharmacological response to synthetic thrombin receptor agonists. Eur J Pharmacol 1994, 253:225-230.
54. Godin D., Rioux F., Marceau F., Drapeau G. Mode of action of thrombin in the rabbit aorta. Br J Pharmacol 1995, 115:903-908.
55. 2 receptors. Hypertension 2003, 41:611-617.
56. Palmer R.M.J., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327:524-526.
57. Palmer R.M.J., Ashton D.S., Moncada S. Vascular endothelial cells synthesize nitric oxide from l arginine. Nature 1988, 333:664-666.
58. Marceau F. Evidence for vascular tone regulation by resident or infiltrating leukocytes. Biochem Pharmacol 1996, 52:1481-1488.
59. Shagdarsuren E., Müller D., Weber C., Zernecke A. Complement activation in vascular remodeling and organ damage. Drug Discov. Today Dis Mech 2008, 5:e299-e306.
60. Marceau F., Hugli T.E. Effect of C3a and C5a anaphylatoxins on guinea-pig isolated blood vessels. J Pharmacol Exp Ther 1984, 230:749-754.
61. Fortin J.P., Bouthillier J., St-Pierre S.A., Marceau F. Contractile effect of anaphylatoxin C5a and of a mimetic peptide on the human umbilical artery: further evidence for leukocyte-dependent vasomotion. J Cardiovasc Pharmacol 2002, 40:815-821.
62. Paczkowski N.J., Finch A.M., Whitmore J.B., Short A.J., Wong A.K., Monk P.N., et al. Pharmacological characterization of antagonists of the C5a receptor. Br J Pharmacol 1999, 128:1461-1466.
63. L'Heureux N., Stoclet J.C., Auger F.A., Lagaud G.J., Germain L., Andriantsitohaina R. A human tissue-engineered vascular media: a new model for pharmacological studies of contractile responses. FASEB J 2001, 15:515-524.
64. Petitclerc E., Levesque L., Grose J.H., Poubelle P.E., Marceau F. Pathologic leukocyte infiltration of the rabbit aorta confers a vasomotor effect to chemotactic peptides through cyclooxygenase-derived metabolites. J Immunol 1996, 156:3426-3434.
65. Morissette G., Petitclerc E., Marceau F. Loss of function of vascular smooth muscle cells by nitric oxide-dependent and -independent interactions with tumorigenic cells. Int J Cancer 2004, 112:830-839.
66. Kenakin T.P. Concentration of drugs in tissues. Pharmacological analysis of drug-receptor interaction 1987, 99-128. Raven Press, New York, USA.
67. 1 receptors in the rabbit aorta. J Pharmacol Exp Ther 2005, 314:1169-1174.
68. Kauffenstein G., Drouin A., Thorin-Trescases N., Bachelard H., Robaye B., D'Orléans-Juste P., et al. NTPDase1 (CD39) controls nucleotide-dependent vasoconstriction in mouse. Cardiovasc Res 2010, 85:204-213.
69. Morissette G., Lodge R., Bouthillier J., Marceau F. Receptor-independent, vacuolar ATPase-mediated cellular uptake of histamine receptor-1 ligands: possible origin of pharmacological distortions and side effects. Toxicol Appl Pharmacol 2008, 229:320-331.
70. 1 receptor?. Am J Physiol Heart Circul Physiol 2003, 285:H277-H282.
71. Babiuk C., Marceau F., St-Pierre S., Regoli D. Kininases and vascular responses to kinins. Eur J Pharmacol 1982, 78:167-174.